Flare Therapeutics to Present Overview of Clinical Candidate FX-909 at AACR Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Flare Therapeutics Inc., a private biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced that it will give an oral presentation highlighting the discovery of its clinical candidate FX-909, at the upcomin...